课题基金 / 基金详情

Description of substrate specificity determinants in Solute Carrier Transporters

Description of substrate specificity determinants in Solute Carrier Transporters
溶质载体转运蛋白中底物特异性决定因素的描述
批准号:
7911487
负责人:
Avner Schlessinger
金额:
$5.05万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-05-01 至 2012-04-30

项目摘要

项目成果

Avner Schlessinger的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请方提供):溶质载体(SLC)超家族成员是控制溶质(包括必需细胞化合物、环境毒素和治疗药物)跨生物膜摄取和流出的膜转运蛋白。这个建议的广泛目的是有助于我们理解个体对药物反应(药物遗传学)的遗传基础,通过提供这个关键膜转运蛋白超家族的底物特异性的全面综合实验和计算描述。该提案的第一个目标是确定人类基因组中新的SLC超家族成员,并阐明SLC家族之间的关系;这将通过绘制区分一个家族的序列,结构和化学特征来实现。将相关蛋白质分类成组将有助于推断结构和功能特征的相似性(例如,折叠、配体结合位点和分子机制)。分类方案很可能告知SLC转运蛋白结构的建模-描述其底物特异性的先决条件。第二个目标是描述选定SLC家族内底物特异性的序列和结构决定因素。这一目标将通过结合计算方法,如序列分析,结构比较,比较建模,配体对接和虚拟筛选,与实验的努力。实验工作将与其他实验室合作进行;它将包括使用各种测定的功能表征,包括配体摄取和动力学测量。第三个目标是利用SLC家族的特异性决定因素信息来开发遗传变异对转运蛋白功能影响的预测模型,该模型将在临床重要底物上进行实验测试。最终,这项研究中获得的结果将有助于我们理解为什么个体对相同药物的反应不同。特别是,研究结果与临床观察到的疾病状态和个体对药物反应的变化之间的相关性可能是朝着个性化医疗迈出的重要一步,极大地有益于公共卫生。 公共卫生相关性:溶质载体(SLC)超家族成员是控制溶质(包括必需的细胞化合物、环境毒素和治疗药物)跨生物膜的摄取和流出的膜转运蛋白。这个建议的主要目的是通过提供这个关键的膜转运蛋白超家族的底物特异性的全面综合的实验和计算描述,有助于我们理解个体对药物反应(药物遗传学)之间的遗传基础。研究结果与临床观察到的疾病状态和个体对药物反应的变化之间的相关性可能是朝着个性化医疗迈出的重要一步,极大地有益于公共卫生。
英文摘要
DESCRIPTION (provided by applicant): Solute Carrier (SLC) superfamily members are membrane transporter proteins that control the uptake and efflux of solutes, including essential cellular compounds, environmental toxins and therapeutic drugs across biological membranes. The broad aim of this proposal is to contribute to our understanding of the genetic basis of variation among individuals' response to drugs (pharmacogenetics), by providing comprehensive integrated experimental and computational description of substrate specificity of this key membrane transporter superfamily. The first goal of this proposal is to identify new SLC superfamily members in the human genome and to elucidate the relationships between SLC families; this will be achieved by mapping sequence, structural and chemical features that distinguish one family from another. The classification into groups of related proteins will be useful for inferring similarities in structural and functional features (e.g., fold, ligand binding site, and molecular mechanism) of uncharacterized proteins based on their characterized aligned homologs. The classification scheme is likely to inform modeling of the SLC transporter structures - a prerequisite for describing their substrate specificities. The second goal is to describe sequence and structure determinants of substrate specificity within selected SLC families. This goal will be accomplished by combining computational methodologies such as sequence analysis, structure comparisons, comparative modeling, ligand docking, and virtual screening, with experimental efforts. The experimental work will be conducted in collaboration with other labs; it will include functional characterization using various assays including ligand uptake and kinetic measurements. The third goal is to utilize the specificity determinants information of the SLC families to develop predictive models for the effects of genetic variation on transporter function, which will be experimentally tested on clinically important substrates. Ultimately, the results obtained in this study will contribute to our understanding of why individuals respond differently to the same drug. In particular, correlation of the study results with clinically observed disease states and variation among individuals in response to drugs can be a significant step toward personalized medicine greatly benefitting public health. PUBLIC HEALTH RELEVANCE: Solute Carrier (SLC) superfamily members are membrane transporter proteins that control the uptake and efflux of solutes, including essential cellular compounds, environmental toxins and therapeutic drugs across biological membranes. The broad aim of this proposal is to contribute to our understanding of the genetic basis of variation among individuals' response to drugs (pharmacogenetics) by providing comprehensive integrated experimental and computational description of substrate specificity of this key membrane transporter superfamily. Correlation of the study results with clinically observed disease states and variation among individuals in response to drugs can be a significant step toward personalized medicine greatly benefitting public health.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identifying New Astrocytic Kir4.1 Channel Modulators for Treating Huntington's Disease
Substrate Specificity Determinants in Nutrient Solute Carrier Transporters
Substrate Specificity Determinants in Nutrient Solute Carrier Transporters
Substrate Specificity Determinants in Cancer-related Solute Carrier Transporters
海外基金